Breast Cancer Clinical Trial

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

Summary

This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

In screening for, and ultimately randomized into, protocol G200802
Give voluntary, written and signed, informed consent for this add-on study
Age 18 to 70 years old
Physically capable of mounting and riding a stationary bicycle
Subject agrees to not significantly alter physical activity or current physical training during the study period

Exclusion Criteria:

Subject has a concomitant medical condition that precludes adequate study treatment compliance or assessment, or increases subject risk, in the opinion of the Investigator
Subjects unwilling to or unable to comply with the protocol
Any other condition which per investigators' judgement may increase subject risk

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

12

Study ID:

NCT02746328

Recruitment Status:

Completed

Sponsor:

GTx

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of Washington, School of Medicine
Seattle Washington, 98109, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

12

Study ID:

NCT02746328

Recruitment Status:

Completed

Sponsor:


GTx

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.